Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11939380 Combination therapies targeting PD-1, TIM-3, and LAG-3

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Camilla Fröhlich0

Mikkel Wandahl Pedersen0

Monika Gad0

Ivan David Horak0

Michael Kragh0

Johan Lantto0

Trine Lindsted0

Michael Monrad Grandal0

...

Date of Patent

March 26, 2024

0

Patent Application Number

165009180

Date Filed

April 5, 2018

0

Patent Citations

US Patent 10550181 Anti-TIM-3 antibody

0

US Patent 11034765 Anti-PD-1 antibodies and compositions

0

US Patent 11390674 Anti-TIM-3 antibodies and compositions

0

US Patent 11359018 Anti-PD-1 antibodies and compositions

0

US Patent 11390676 Anti-LAG-3 antibodies and compositions

0

US Patent 8354509 Antibodies to human programmed death receptor PD-1

0

US Patent 8927697 PD-1 specific antibodies and uses thereof

0

Patent Primary Examiner

Nelson B Moseley, II

0

CPC Code

0

0

0

0

0

0

0

0

...

Patent abstract

This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11939380 Combination therapies targeting PD-1, TIM-3, and LAG-3

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.